MedicaidCoverageLow impact
Newsletter Vol. 28, No.19
New Jersey Medicaid·NJ · Endocrinology, Family Medicine, Internal Medicine +1 more·Provider Notice
We identified it
Jun 20, 2026
Summary
The New Jersey Drug Utilization Review Board (DURB) is issuing clinical guidance recommending metformin as the first-line pharmacologic treatment for type 2 diabetes, citing superior safety profile, cost-effectiveness (average savings of $181 per claim vs. other diabetic drugs), and robust clinical evidence. This is an advisory bulletin to encourage broader prescribing of metformin before alternative antidiabetic agents, with updated safety guidance on use in chronic kidney disease based on eGFR thresholds rather than serum creatinine.
Action Required
This is an informational/advisory bulletin from the New Jersey DURB, not a mandated policy change. No immediate billing or workflow changes are required. However, providers should be aware that: (1) Prescribers should prioritize metformin as first-line therapy for type 2 diabetes unless contraindicated or not tolerated; (2) Medical necessity documentation may be requested if non-metformin diabetic agents are prescribed first; (3) Claims reviewers at NJ Medicaid programs may flag cases where alternative diabetic drugs were used without prior metformin trial. Recommendation: Notify endocrinology and primary care providers of this guidance to align prescribing practices with state recommendations. No changes to billing systems, encounter forms, or prior authorization workflows are required at this time.